Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical… (NCT07444073) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
Singapore440 participantsStarted 2026-02-02
Plain-language summary
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
Who can participate
Age range40 Years – 89 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
* BMI of ≥ 27.5 kg/m2 (if Asian) or 30 kg/m2 (if non-Asian); OR
* BMI of ≥ 23 kg/m2 (if Asian) / 25 (if non-Asian) kg/m2 in the presence of a weight-related chronic condition (e.g., diabetes, pre-diabetes, polycystic ovarian syndrome, hypertension, fatty liver, high cholesterol).
Exclusion Criteria:
* Pregnancy or lactation.
* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
* Concomitant anti-diabetic therapy.
* Active cancer on chemotherapy or immunotherapy.
* Known hypersensitivity or contraindications to GLP-1 RAs.
* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.